Drug Profile
Research programme: thyroid cancer therapeutics - MGI Pharma
Alternative Names: AKR-201; Tetrac; Tetraiodothyroacetic acidLatest Information Update: 23 Feb 2010
Price :
$50
*
At a glance
- Originator Beartownpharma
- Developer AkaRx
- Class
- Mechanism of Action Thyrotropin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thyroid cancer
Most Recent Events
- 06 Jan 2010 AkaRx has been acquired by Eisai Inc
- 29 Jan 2008 MGI Pharma has been acquired by Eisai
- 12 Oct 2007 AKR 201 licensed to MGI Pharma worldwide